Codexis, Inc. (NASDAQ:CDXS) SVP James Lalonde sold 15,000 shares of the stock in a transaction on Tuesday, July 17th. The stock was sold at an average price of $15.40, for a total value of $231,000.00. Following the sale, the senior vice president now owns 202,566 shares in the company, valued at approximately $3,119,516.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
James Lalonde also recently made the following trade(s):
Get Codexis alerts: On Monday, May 14th, James Lalonde sold 10,000 shares of Codexis stock. The shares were sold at an average price of $13.09, for a total value of $130,900.00.Shares of Codexis opened at $15.90 on Friday, according to Marketbeat. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.61 and a current ratio of 1.67. Codexis, Inc. has a 12-month low of $4.80 and a 12-month high of $16.80.
Codexis (NASDAQ:CDXS) last issued its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.02). Codexis had a negative net margin of 36.06% and a negative return on equity of 87.65%. The firm had revenue of $14.04 million for the quarter, compared to analyst estimates of $13.50 million. analysts forecast that Codexis, Inc. will post -0.27 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently modified their holdings of CDXS. Lord Abbett & CO. LLC acquired a new position in shares of Codexis during the first quarter valued at $7,544,000. Wells Fargo & Company MN lifted its stake in Codexis by 156.4% in the fourth quarter. Wells Fargo & Company MN now owns 1,002,086 shares of the biotechnology company’s stock valued at $8,367,000 after buying an additional 611,289 shares during the period. Baillie Gifford & Co. lifted its stake in Codexis by 25.0% in the first quarter. Baillie Gifford & Co. now owns 2,302,979 shares of the biotechnology company’s stock valued at $25,332,000 after buying an additional 460,578 shares during the period. Bradley Foster & Sargent Inc. CT acquired a new position in Codexis in the first quarter valued at about $4,955,000. Finally, Spark Investment Management LLC acquired a new position in Codexis in the first quarter valued at about $1,405,000. 65.89% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages have recently issued reports on CDXS. ValuEngine raised Codexis from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. BidaskClub raised Codexis from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, June 20th. Stephens began coverage on Codexis in a research note on Wednesday, May 16th. They set an “overweight” rating and a $16.00 price target on the stock. Zacks Investment Research lowered Codexis from a “buy” rating to a “sell” rating in a research note on Wednesday, May 16th. Finally, Cowen began coverage on Codexis in a research note on Tuesday, June 19th. They set an “outperform” rating and a $18.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $14.20.
Codexis Company Profile
Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.
Recommended Story: Should you buy a closed-end mutual fund?
No comments:
Post a Comment